Although anticoagulant therapy with warfarin and recently with direct thrombin inhibitor dabigatran and the selective factor Xa inhibitors apixaban and rivaroxaban is recommended to reduce stroke risk in AF, alternative strategies are needed for patients who cannot tolerate or who have contraindications to use anticoagulation agents. The gene discussed is F10; the disease is stroke disorder.